Disease

ALK Positive Non Small Cell Lung Cancer (NSCLC)

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 4, 2026 · INTERVENTIONAL STUDY

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

ClinicalTrials.gov

This is a clinical trial registry record describing an expanded access program with no results reported; it documents planned access to an investigational drug for patients who cannot enroll in formal trials.

Insufficient InformationNuvalent NCT06834074 ALK Positive Non Small Cell Lung Cancer (NSCLC)

Reported

Primary conditionALK-positive non-small cell lung cancer (NS…

Investigational agentNeladalkib (NVL-655)

Program typeExpanded Access Program

AUG 20, 2026 · PHASE 2/3 TRIAL

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

ClinicalTrials.gov

This is a Phase 2/3 registry record with no reported results; it describes a planned pharmacogenomics study exploring SNP associations with alectinib efficacy and toxicity in ALK-positive NSCLC, currently active but not recruiting.

PreliminaryAlectinib Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair ALK Positive Non Small Cell Lung Cancer (NSCLC)

Reported

Planned sample size600

PhasePhase 2/Phase 3

Primary outcome measure 1Measure and Report Alectinib Drug Targets'…